National Taiwan University Hospital: Carcinoma, Non-Small-Cell Lung trials

The registry lists 26 Carcinoma, Non-Small-Cell Lung studies with National Taiwan University Hospital as lead sponsor. 6 are open to participants now and 0 have results posted.

Phase 1 2Phase 2 9Phase 3 1No phase 15(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung CancerRecruitingNCT07738172Phase 3
• Nurse-Led Caregiver Support for Older Adults With Advanced Lung CancerRecruitingNCT07708870Not applicable
• XR-Assisted PET/CT Navigation for Cervical Lymph Node Dissection in Lung CancerNot yet recruitingNCT07593872Not applicable
• 3D Virtual Resection for Predicting Lung Function in VATSRecruitingNCT07436598
• Effects of a Visual Interactive LINE Chatbot on Self-Management of EGFR-TKI Related Side Effects in Patients With Lung CancerNot yet recruitingNCT07310589Not applicable
• Primary Tumor Resection With EGFR TKI for Stage IV NSCLCRecruitingNCT05215548Phase 2
• The Role of Protein Tyrosine Kinase 7 (PTK7) in Non-small Cell Lung CancerCompletedNCT04018183
• Folate One-carbon Malnutrition as the Metabostemness Risk Factor of Malignancy Tumor Development of NSCLC PatientsStatus unknownNCT03504098
• Effects of Nonintubated Thoracoscopic Lobectomy on Lung ProtectionStatus unknownNCT03471884Not applicable
• Clinical Application of MR-PET in Non-small Cell Lung Cancer: Diagnosis, Treatment Outcome, and Prognosis PredictionStatus unknownNCT03053804Not applicable
• Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II TrialStatus unknownNCT02655536Phase 2
• Erlotinib Monotherapy Versus Docetaxel and Cisplatin as Neoadjuvant Therapy in Patients of stageIIIA Lung caStatus unknownNCT02036359Phase 2
• Selumetinib in Combination With Gefitinib in NSCLC PatientsCompletedNCT02025114Phase 1/2
• Genotyping of Non-small Cell Lung CancerStatus unknownNCT02002117
• AUY922 in Patient With Stage IV NSCLCCompletedNCT01922583Phase 2
• Crizotinib Efficacy In Non-Small Cell Lung Cancer Patients With Anaplastic Lymphoma Kinase TranslocationStatus unknownNCT01637597
• e- Ab Sensor-based Real-time Detection of Mutant EGFR in Clinical Specimens From Patients of Non-small Cell Lung CancerStatus unknownNCT01359436Not applicable
• Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)Status unknownNCT01147211Phase 1
• Gene Mutations in Non-Small Cell Lung Cancer CellsStatus unknownNCT00977509
• DNA Repair Genes and Outcomes in Patients With Stage III NSCLCStatus unknownNCT00797238
• The Utility and Cost-Effectiveness Analysis of 18F-FDG PETin Staging Potential Operable Non-Small Cell Lung CancerStatus unknownNCT00364663
• Docetaxel Plus Cisplatin Followed by Gemcitabine Versus Gemcitabine Plus Cisplatin Followed by Docetaxel for Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00173888Phase 2
• Iressa as a First-Line Treatment in Chemonaive Patients With Inoperable Non-Small Cell Lung CancerCompletedNCT00173875Phase 2
• PharmacoEconomic Assessment IRESSA® in the Treatment of Non-Small-Cell Lung Cancer (NSCLC)Status unknownNCT00173524
• Phase II Study of Docetaxel Plus CDDP for NSCLC Stage IIICompletedNCT00172380Phase 2
• Gemcitabine/Cisplatin Versus Gemcitabine/Epirubicin for Non-Small Cell Lung Cancer (NSCLC)CompletedNCT00154739Phase 2